8 GLP-1 Programs People Actually Trust Right Now (And Why They Keep Coming Up)

A friend started researching GLP-1 options last spring and quickly ran into the same wall most people hit: dozens of telehealth brands, wildly different price structures, and almost no way to tell which ones were cutting corners. She spent three weeks reading Reddit threads, Facebook groups, and patient forums before settling on one. The names below are the ones that kept appearing in those conversations, and for reasons worth understanding.

1. FormBlends

FormBlends stands out mostly because it does something unusual: weight-loss medications and a full peptide catalog sit inside the same clinician-supervised program, dispensed through a single licensed pharmacy. Most GLP-1 telehealth brands stop at semaglutide or tirzepatide. Most peptide sellers operate as research-only suppliers with no prescriber in the loop. FormBlends sits at a different intersection.

The pharmacy operates under 503A compounding standards with FDA oversight. A physician reviews each intake before anything ships. Coverage reaches 47 states, with cold-chain shipping included. Importantly, compounded medications here are not FDA-approved finished drugs, and the company does not imply otherwise.

On purity, FormBlends publishes actual numbers per product rather than a vague certificate of analysis. Mass spectrometry confirmation on tirzepatide batches, for example, returns a reported identity purity of 99.3%. That kind of specific, product-level disclosure is genuinely rare in this space.

Pricing is flat and visible before signup. No membership fee stacked on top of a separate medication charge. The per-vial cost appears on the page, and that is the cost. In a market full of introductory-month pricing that balloons later, that transparency gets noticed.

One thing to hold onto: the peptide side of the catalog (BPC-157, sermorelin, NAD+, and so on) carries mostly preclinical or early-stage human evidence. FormBlends is not a substitute for a specialist, but as a starting point for someone who wants both GLP-1 access and a research-backed peptide program under real pharmacy oversight, it is the most complete option in this list.

2. Mochi Health

Mochi comes up constantly in weight-loss forums, and the reason is specific. The platform staffs board-certified obesity-medicine specialists rather than routing patients through general practitioners. That distinction matters for people who have already been dismissed by a primary care doctor. Compounded semaglutide runs around $99 per month, tirzepatide around $199. Branded medications are also available with insurance support. The clinical monitoring is more hands-on than most telehealth options at this price range.

3. Ro Body

Ro has been around long enough to feel established, and its prior-authorization team is one of the reasons people recommend it. Getting branded Wegovy or Zepbound covered by insurance is a process, and Ro actually helps patients work through it rather than defaulting immediately to cash-pay compounded options. The monthly membership starts low, but medication is billed separately, so patients should calculate the real combined cost before committing. Polished app, reliable communication.

4. Hims and Hers

After a March 2026 settlement with Novo Nordisk, Hims and Hers stopped offering compounded semaglutide to new patients and shifted toward branded medications. Wegovy via the platform runs about $299 per month without insurance, oral Wegovy around $249, Zepbound roughly $399. For patients with commercial insurance plus a manufacturer savings card, those numbers can drop to nearly nothing. The onboarding is fast, the app is clean, and for insured patients, the brand infrastructure around prior authorizations and follow-up is reliable.

5. Henry Meds

Speed is the consistent theme in Henry Meds reviews. People report receiving their first shipment within 24 to 72 hours of approval, which is faster than most competitors. First-month pricing often lands in the $179 to $249 range for compounded GLP-1. The tradeoff mentioned regularly in forums: ongoing clinical monitoring is lighter than platforms like Mochi or Form Health. Good fit for someone who knows what they want and does not need intensive coaching.

6. PlushCare

PlushCare operates differently from most names on this list. It prescribes FDA-approved branded drugs, period. No compounded alternatives. The membership is about $19.99 per month, and the platform accepts insurance, often enabling same-day appointments. It functions more like a standard telehealth primary care service that happens to write GLP-1 scripts than like a dedicated weight-loss program. For patients whose insurance covers Ozempic or Wegovy and who simply need a prescriber, PlushCare gets recommended frequently for its accessibility.

7. Form Health

Form Health is the expensive, high-touch option. The monthly program fee sits around $299 before labs and medication are added. What patients get is a paired physician and registered dietitian model, with personalized plans that go well beyond a quick check-in. The people who recommend it tend to have either good insurance or a specific reason to want that level of accountability. Not the entry point for most, but for someone who has tried lower-support programs and stalled, the structure is genuinely different.

8. Calibrate

Calibrate builds its program around a 12-month commitment and leans harder into behavior change than any other platform here. The coaching infrastructure is extensive. It works best for insured patients because the program separates its coaching fee from medication costs, and medication only makes financial sense when insurance absorbs a significant portion of it. People in patient communities recommend Calibrate specifically when they want a program that treats lifestyle change as the actual intervention rather than an accessory to the drug.

What 2026 Changed

Worth knowing before picking any of these: FDA warning letters went out to more than 30 compounding and telehealth companies in early 2026 over how they marketed GLP-1 products. Several major platforms pulled back from compounded semaglutide, partly due to the Novo Nordisk settlement that took effect in March. The market shifted fast. Some brands adapted by moving toward branded-drug pipelines; others, like FormBlends, kept compounding options available and expanded the catalog. Neither path is inherently safer, but understanding which direction a company moved helps clarify what you are actually signing up for.

Before starting any GLP-1 program or peptide regimen, run the specifics by a clinician who knows your full health history. This article reflects patterns from public patient communities and independently verifiable brand information, not a personal assessment of any individual’s situation.